P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY

• Vania Hungria,
• Katja Weisel,
• Brooke Currie,
• Sue Perera,
• Neal Sule,
• Wei He,
• Astrid Mckeown,
• Sandhya Sapra,
• Linda Nelsen,
• Mary LI,
• Sophie Barale,
• Julia Boyle,
• Kaytlyn Mcpoyle,
• Meletios A. Dimopoulos

Affiliations

Vania Hungria

1 Department of Hematology, Clinica São Germano São Paulo, Sao Paolo, Brazil

Katja Weisel

2 University Medical Center of Hamburg-Eppendorf, Hamburg, Germany

Brooke Currie

3 GSK, Rockville, United States

Sue Perera

4 GSK, London, United Kingdom

Neal Sule

5 GSK, Upper Providence, United States

Wei He

6 GSK, Waltham, United States

Astrid Mckeown

7 GSK, Stevenage, United Kingdom

Sandhya Sapra

5 GSK, Upper Providence, United States

Linda Nelsen

5 GSK, Upper Providence, United States

Mary LI

5 GSK, Upper Providence, United States

Sophie Barale

8 GSK, Paris, France

Julia Boyle

4 GSK, London, United Kingdom

Kaytlyn Mcpoyle

5 GSK, Upper Providence, United States

Meletios A. Dimopoulos

9 National and Kapodistrian University of Athens School of Medicine, Athens, Greece